Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy
Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy
复制标题
DOI：
10.1101/cshperspect.a036921
复制
发表时间：
2020-04-01
影响因子：
5.4
通讯作者：
Negro，Francesco
中科院分区：
文献类型：
--
作者：
Negro，Francesco
全球每年有7110万人感染丙型肝炎病毒，并导致40万人死亡。丙型肝炎病毒主要感染肝脏，引起急性和慢性坏死性炎症损害，可能进展为肝硬变和肝细胞癌。此外，丙型肝炎病毒还与几种肝外表现有关。安全有效的直接作用抗病毒药物(DAA)的出现，使消除这一公共卫生祸害的梦想在中期内成为可能。使用DAA方案的前瞻性研究表明，丙型肝炎病毒清除在肝脏相关和非肝脏相关死亡率方面都有好处。
The hepatitis C virus (HCV) infects 71.1 million persons and causes 400,000 deaths annually worldwide. HCV mostly infects the liver, causing acute and chronic necroinflammatory damage, which may progress toward cirrhosis and hepatocellular carcinoma. In addition, HCV has been associated with several extrahepatic manifestations. The advent of safe and effective direct-acting antivirals (DAAs) has made the dream of eliminating this public health scourge feasible in the medium term. Prospective studies using DAA-based regimens have shown the benefit of HCV clearance in terms of both liver- and non-liver-related mortality.